Info

aAll-cause death, all-cause amputation, or new thrombosis within 37-day study period.

bSeverity ranking: all-cause death > all-cause amputation > new thrombosis; patients with multiple outcomes counted once.

cPatient counted only once if multiple events occurred.

Abbreviations: ARG, argatroban; HIT, heparin-induced thrombocytopenia.

Source: Lewis et al., 2001.

aAll-cause death, all-cause amputation, or new thrombosis within 37-day study period.

bSeverity ranking: all-cause death > all-cause amputation > new thrombosis; patients with multiple outcomes counted once.

cPatient counted only once if multiple events occurred.

Abbreviations: ARG, argatroban; HIT, heparin-induced thrombocytopenia.

Source: Lewis et al., 2001.

Argatroban therapy, compared with controls, significantly reduced death due to thrombosis in each study arm (HIT, p = 0.005; HITTS, p < 0.001). There were no between-group differences in all-cause mortality. The incidence of amputation (as the most severe outcome) was similar between groups. Argatroban therapy also significantly reduced the percentage of patients experiencing new thrombosis in each study arm (HIT, p < 0.001; HITTS, p = 0.044).

Argatroban-treated patients achieved therapeutic aPTTs generally at first measure (i.e., within 4-5 h of starting therapy) and maintained these levels throughout infusion. Resolution of thrombocytopenia occurred by day 3 in 53% of argatroban-treated patients with HIT and 58% of patients having HITTS. Compared with controls, argatroban-treated patients had a significantly more rapid rise in platelet counts.

0 0

Post a comment